A single-dose film-coated tablet of this fixed-dose combination drug, Hydrochlorothiazide, and Valsartan, available in 160 mg/12.5 mg and 80 mg/12.5 mg dosages, consists of 160 mg or 80 mg of Valsartan USP or IP equivalents and Hydrochlorothiazide USP equivalent to 12.5 mg along with other active ingredients.


Usage of this drug is indicated in the treatment of moderate to severe ranges of hypertension and helps in decreasing the overall workload on the heart, causing palpitations in patients with essential hypertension.

Side effects

A mild to moderate range of side effects have been observed. Side effects such as dizziness, nausea, headache, fatigue, lightheadedness, blurred vision, decreased white blood cell count, unusual skin rash, easy bruising, and stuffiness of the nose.


This medication is to be prescribed cautiously in patients with severe renal dysfunction and hepatic disorders, and patients with diabetes, and not to be prescribed in patients working with machinery, suffering from severe dizziness, or before driving.


This medication is contraindicated in patients with a history of hypersensitivity to this drug or any of its constituents; in patients with severe hepatic disorders; renal impairment; hyperglycemia; diabetes mellitus; and in patients with anuria, hyponatremia, and hypovolemia.

Dosage and administration

In adults, the usual dosage in cases of hypertension consists of 1 tablet per day to be administered orally, with a dose of 80–160 mg of valsartan and 12.5 mg–25 mg of hydrochlorothiazide; the dose should not exceed 320 mg/25 mg of valsartan and hydrochlorothiazide overall.


We have also established roots and begun this new venture in other countries as well, such as Sudan, South America, Nigeria, Laos, Abu Dhabi, and Nepal.

Available Forms